Acadian Asset Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $427M | Sell |
2,262,369
-67,802
| -3% | -$12.8M | 0.51% | 45 |
|
|
2026
Q1 | $457M | Buy |
2,330,171
+1,240,882
| +114% | +$239M | 0.65% | 36 |
|
|
2025
Q4 | $200M | Buy |
1,089,289
+24,618
| +2% | +$4.32M | 0.33% | 67 |
|
|
2025
Q3 | $163M | Buy |
1,064,671
+42,746
| +4% | +$6.47M | 0.29% | 71 |
|
|
2025
Q2 | $143M | Buy |
1,021,925
+980,882
| +2,390% | +$137M | 0.29% | 80 |
|
|
2025
Q1 | $6.03M | Sell |
41,043
-24,026
| -37% | -$3.48M | 0.02% | 450 |
|
|
2024
Q4 | $8.52M | Sell |
65,069
-193,020
| -75% | -$27M | 0.02% | 396 |
|
|
2024
Q3 | $40.2M | Buy |
258,089
+252,326
| +4,378% | +$40.7M | 0.12% | 170 |
|
|
2024
Q2 | $897K | Sell |
5,763
-404
| -7% | -$60.8K | ﹤0.01% | 1031 |
|
|
2024
Q1 | $834K | Sell |
6,167
-6,963
| -53% | -$922K | ﹤0.01% | 892 |
|
|
2023
Q4 | $1.77M | Sell |
13,130
-6,776
| -34% | -$881K | 0.01% | 699 |
|
|
2023
Q3 | $2.69M | Sell |
19,906
-43,221
| -68% | -$5.9M | 0.01% | 603 |
|
|
2023
Q2 | $9.03M | Buy |
63,127
+46,138
| +272% | +$6.79M | 0.04% | 316 |
|
|
2023
Q1 | $2.35M | Sell |
16,989
-12,222
| -42% | -$1.64M | 0.01% | 661 |
|
|
2022
Q4 | $3.96M | Buy |
29,211
+19,456
| +199% | +$2.44M | 0.02% | 509 |
|
|
2022
Q3 | $1.07M | Buy |
9,755
+7,563
| +345% | +$959K | 0.01% | 790 |
|
|
2022
Q2 | $289K | Buy |
2,192
+1,930
| +737% | +$253K | ﹤0.01% | 1111 |
|
|
2022
Q1 | $34K | Sell |
262
-10,958
| -98% | -$1.31M | ﹤0.01% | 1508 |
|
|
2021
Q4 | $1.31M | Sell |
11,220
-27,870
| -71% | -$3.28M | ﹤0.01% | 766 |
|
|
2021
Q3 | $4.69M | Sell |
39,090
-35,165
| -47% | -$4.09M | 0.02% | 462 |
|
|
2021
Q2 | $8.89M | Sell |
74,255
-24,870
| -25% | -$2.73M | 0.03% | 336 |
|
|
2021
Q1 | $9.86M | Sell |
99,125
-75,508
| -43% | -$7.59M | 0.04% | 336 |
|
|
2020
Q4 | $17.5M | Buy |
174,633
+58,122
| +50% | +$6.16M | 0.07% | 242 |
|
|
2020
Q3 | $12.8M | Buy |
+116,511
| New | +$13M | 0.05% | 277 |
|
|
2018
Q3 | – | Sell |
-1,081
| Closed | -$76K | – | 1659 |
|
|
2018
Q2 | $76K | Sell |
1,081
-1,606
| -60% | -$116K | ﹤0.01% | 1306 |
|
|
2018
Q1 | $188K | Sell |
2,687
-301,145
| -99% | -$20.9M | ﹤0.01% | 1072 |
|
|
2017
Q4 | $21.1M | Sell |
303,832
-360,257
| -54% | -$24.3M | 0.09% | 189 |
|
|
2017
Q3 | $45M | Sell |
664,089
-94,454
| -12% | -$5.97M | 0.2% | 121 |
|
|
2017
Q2 | $51.7M | Sell |
758,543
-33,133
| -4% | -$2.16M | 0.23% | 106 |
|
|
2017
Q1 | $49.3M | Buy |
791,676
+747,363
| +1,687% | +$43.5M | 0.23% | 107 |
|
|
2016
Q4 | $2.42M | Hold |
44,313
| – | – | 0.01% | 551 |
|
|
2016
Q3 | $2.91M | Buy |
+44,313
| New | +$2.9M | 0.01% | 452 |
|
|
2014
Q4 | – | Sell |
-542
| Closed | -$39K | – | 1265 |
|
|
2014
Q3 | $39K | Sell |
542
-748
| -58% | -$54.7K | ﹤0.01% | 879 |
|
|
2014
Q2 | $96K | Sell |
1,290
-1,837
| -59% | -$133K | ﹤0.01% | 865 |
|
|
2014
Q1 | $203K | Buy |
3,127
+18
| +0.6% | +$1.16K | ﹤0.01% | 778 |
|
|
2013
Q4 | $185K | Sell |
3,109
-401
| -11% | -$21.8K | ﹤0.01% | 814 |
|
|
2013
Q3 | $182K | Buy |
3,510
+209
| +6% | +$10.5K | ﹤0.01% | 757 |
|
|
2013
Q2 | $156K | Buy |
+3,301
| New | +$168K | ﹤0.01% | 702 |
|
Other funds holding AZN
EPGL
VCM
VAM
VFT
Acadian Asset Management's AZN Position: Q2 2026 in Review
Acadian Asset Management reduced its AstraZeneca (AZN) stake by 2.9% in Q2 2026, selling an estimated $12.8M and leaving 2,262,369 shares worth $427M. The position accounts for 0.51% of the portfolio, ranked #45.
Acadian Asset Management first reported a position in AZN in Q2 2013 and has held it in 38 quarters since. The position peaked at $457M in Q1 2026. 1,253 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Acadian Asset Management held 2,262,369 shares of AstraZeneca worth $427M as of Q2 2026.
- Acadian Asset Management sold 67,802 AstraZeneca shares in Q2 2026, an estimated $12.8M.
- AstraZeneca made up 0.51% of Acadian Asset Management's portfolio in Q2 2026, its #45 holding.
- Acadian Asset Management first reported a position in AstraZeneca in Q2 2013 and has held it in 38 quarters since.
- Acadian Asset Management's AstraZeneca position peaked at $457M in Q1 2026.
- 1,253 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.